^
Association details:
Evidence:
Evidence Level:
Resistant: A2 - Guideline
New
Source:
Excerpt:
Regimens for relapsed or refractory Ph-positive ALL…Bosutinib has minimal activity against F317L mutation. Nilotinib may be preferred over bosutinib in patients with F317L mutation